Joe Jimenez, CEO of Novartis discusses whether the U.S. affordable care act has increased the cost of business.» Read More
Oct 28- Biogen Idec on Monday reported $286 million in third-quarter sales of its high-profile new multiple sclerosis drug Tecfidera, providing fresh evidence that the medicine is off to an impressive launch and exceeding expectations.
*China sales slump 61 percent as doctors shun GSK products. LONDON, Oct 23- GlaxoSmithKline's drug sales in China slumped 61 percent in the third quarter, hit by a bribery scandal that has damaged its ability to market products in the country and pushed some sales into the hands of rivals.
GlaxoSmithKline's pharmaceutical and vaccine sales to China tumbled 61 percent in the third quarter, with the drugmaker hit by an ongoing bribery investigation.
LONDON, Oct 23- GlaxoSmithKline's drug sales in China tumbled 61 percent in the third quarter, hit by a bribery scandal that has damaged its ability to market medicines in the country.
European shares closed higher following the latest U.S. jobs report.
U.S. stock index futures tread water on Tuesday, ahead of the publication of the government's delayed non-farm payrolls data for September.
Andrew Weiss, head of pharma and biotech research at Vontobel, says most products in Novartis' pipeline will face tough competition and incur large marketing costs.
Deutsche Lufthansa fell 3.8 percent, the top FTSEurofirst 300 faller, after it said operating profit for the first nine months of the year fell to about 660 million euros from 907 million in the year-earlier period.
Concerns that flu could mean an increase in staff sick days has prompted some companies to arrange flu jabs for their employees – boosting sales for some drugs companies.
*CEO says growth in China still strong. ZURICH, Oct 17- Strong demand for Roche's speciality cancer medicines, many of which are bought privately in emerging markets, has helped it defy an expected slowdown in sales in China following a crackdown on sales practices there.
Hector Sants’ break from his role as chief compliance officer at Barclays due to stress has highlighted the strains on banks’ internal policemen.
Emerging markets still offer room for growth, Roche's CEO told CNBC after the pharma posted an 8 percent increase in third-quarter sales.
Veeva offers customer relationship management and content management software to the life sciences industry, competing with companies such as Oracle Corp, Cegedim SA of France and EMC Corp.. The company's software is used by 33 of the 50 largest drug makers, including Novartis AG, Merck& Co, Eli Lilly and Co and Bayer Healthcare AG, it said in its IPO filing.
LONDON, Oct 16- Mark Reilly, GlaxoSmithKline's former head of operations in China, is helping anti-corruption officials in the country who are investigating allegations of extensive bribery by the drugmaker. One person familiar with the situation said Reilly had been requested to remain in China while the investigations proceeded and was happy to do so.
The following is a list of possible candidates to replace Woodcock, drawn from interviews with some two-dozen people inside and outside the FDA who have worked with Woodcock and are familiar with the demands of the job. Rachel Sherman, Associate Director of Medical Policy at the FDA's Center for Drug Evaluation and Research.
*Company says controls, training in Japan were inadequate. TOKYO, Oct 3- Novartis AG said on Thursday it had overhauled management operations and sanctioned key staff in Japan after a scandal involving research into its Diovan blood pressure drug in the country.
TOKYO, Oct 3- Novartis AG said on Thursday it did not expect a scandal over the marketing of its Diovan blood pressure drug in Japan to have a significant impact on the company, but acknowledged sales of the drug had fallen.
Oct 2- Otsuka Holdings Co's $886 million bid for Astex Pharmaceuticals Inc has run into opposition from an activist shareholder who says the deal significantly undervalues the U.S. biotech firm- a charge that Astex has denied.
TOKYO, Sept 30- Japan's health ministry will investigate the Japanese unit of Novartis AG, Japanese media said, after a ministry panel said it may have violated Japanese law when it cited studies based on manipulated data to promote its blood pressure drug Diovan.